

Treatment with interferon beta-1b delays conversion to MS in patients with clinically isolated syndromes

Neurology

67, 1242-1249

DOI: 10.1212/01.wnl.0000237641.33768.8d

Citation Report

#	ARTICLE	IF	CITATIONS
1	Acute demyelinating optic neuritis. Expert Review of Ophthalmology, 2006, 1, 159-170.	0.6	3
2	Anti-inflammatory strategies for the treatment of multiple sclerosis – tryptophan catabolites may hold the key. Drug Discovery Today: Therapeutic Strategies, 2006, 3, 401-408.	0.5	7
4	The curious incident of disability in multiple sclerosis trials. Lancet Neurology, The, 2006, 5, 899-900.	10.2	8
5	'ACTRIMS ABSTRACTS: EMERGING THERAPIES IN MULTIPLE SCLEROSIS Basic and Clinical Issues in Multiple Sclerosis Research ACTRIMS ? 12th annual meeting, June 2, 2007 Washington, DC'. Multiple Sclerosis Journal, 2007, 13, 1205-1244.	3.0	2
6	Neurosurgery in Parkinson disease: A distressed mind in a repaired body?. Neurology, 2007, 68, 1164-1165.	1.1	5
7	Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology, 2007, 68, 1161-1161.	1.1	2
8	Prior TIA, lipid-lowering drug use, and physical activity decrease ischemic stroke severity. Neurology, 2007, 68, 1162-1163.	1.1	3
9	Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis. New England Journal of Medicine, 2007, 356, 1888-1889.	27.0	6
10	Magnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study. Archives of Neurology, 2007, 64, 1292.	4.5	46
12	Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology, 2007, 68, 1163-1164.	1.1	94
13	Multifocal motor neuropathy with and without conduction block: A single entity?. Neurology, 2007, 68, 1161-1162.	1.1	3
14	Optic Neuritis. Seminars in Neurology, 2007, 27, 211-220.	1.4	17
15	The safety and efficacy of IFN- β products for the treatment of multiple sclerosis. Expert Opinion on Drug Safety, 2007, 6, 279-288.	2.4	25
16	Medication Use as a Confounding Factor in the Use of the Cerebrospinal Fluid tau/ β -Amyloid42 Ratio. Archives of Neurology, 2007, 64, 1357.	4.5	2
17	Medication Use as a Confounding Factor in the Use of the Cerebrospinal Fluid tau/ β -Amyloid42 Ratio – Reply. Archives of Neurology, 2007, 64, 1357.	4.5	0
19	Evidence-based medicine and clinical trials. Neurology, 2007, 68, S3-S7.	1.1	7
20	Spincther Symptoms as Predictors of Long-term Disability in Multiple Sclerosis – Reply. Archives of Neurology, 2007, 64, 1359.	4.5	0
21	Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice. Current Opinion in Neurology, 2007, 20, 281-285.	3.6	40

#	ARTICLE	IF	CITATIONS
23	DISEASE-MODIFYING THERAPIES. CONTINUUM Lifelong Learning in Neurology, 2007, 13, 144-180.	0.8	0
24	Natural history of multiple sclerosis: risk factors and prognostic indicators. Current Opinion in Neurology, 2007, 20, 269-274.	3.6	109
25	Treatment and treatment trials in multiple sclerosis. Current Opinion in Neurology, 2007, 20, 286-293.	3.6	43
26	Multiple Sclerosis: Current and Future Treatment Options. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2007, 7, 292-299.	1.2	3
27	Interferon- β and neuroprotection in multiple sclerosisâ€”Facts, hopes and phantasies. Experimental Neurology, 2007, 203, 1-4.	4.1	19
28	The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis. Clinical Neurology and Neurosurgery, 2007, 109, 344-349.	1.4	13
29	Interferons in multiple sclerosis: Ten years' experience. Biochimie, 2007, 89, 899-902.	2.6	19
30	Interferon beta in multiple sclerosis: how much BENEFIT?. Lancet, The, 2007, 370, 363-364.	13.7	12
31	Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet, The, 2007, 370, 389-397.	13.7	468
32	Treating clinically isolated syndromes suggestive of MS â€” Authors' reply. Lancet, The, 2007, 370, 2000-2001.	13.7	0
34	Interferon- β 1b in multiple sclerosis. Expert Review of Neurotherapeutics, 2007, 7, 227-239.	2.8	38
35	Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis. New England Journal of Medicine, 2007, 356, 371-378.	27.0	236
36	The role of optical coherence tomography in multiple sclerosis: Expert panel consensus. Journal of the Neurological Sciences, 2007, 263, 3-14.	0.6	89
37	Targeting interferons in multiple sclerosis. Drug Discovery Today: Therapeutic Strategies, 2007, 4, 49-55.	0.5	0
38	Interferon- β Treatment for Multiple Sclerosis. Neurotherapeutics, 2007, 4, 633-646.	4.4	68
39	Pharmacological Properties, Toxicology and Scientific Rationale for the use of Natalizumab (Tysabri®) in Inflammatory Diseases. CNS Neuroscience & Therapeutics, 2007, 13, 79-95.	4.0	98
40	Predictive value of clinical characteristics for ?benign? multiple sclerosis. European Journal of Neurology, 2007, 14, 885-889.	3.3	39
41	Relationship between the extent of T2 lesions and the onset of secondary progression in multiple sclerosis. European Journal of Neurology, 2007, 14, 1210-1215.	3.3	9

#	ARTICLE	IF	CITATIONS
42	Analysis of NAMCS data for multiple sclerosis, 1998â€“2004. BMC Medicine, 2007, 5, 6.	5.5	10
43	MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurology, The, 2007, 6, 677-686.	10.2	292
44	The fragile benefit of BENEFIT. Lancet Neurology, The, 2007, 6, 753-754.	10.2	6
45	Relapsing-remitting MS: does one size fit all?. Progress in Neurology and Psychiatry, 2007, 11, 7-8.	0.9	1
46	Current treatment options in multiple sclerosis. Current Treatment Options in Neurology, 2007, 9, 176-86.	1.8	10
48	Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. Journal of Neurology, 2007, 254, 160-168.	3.6	52
49	Multiple sclerosis therapy: An update on recently finished trials. Journal of Neurology, 2007, 254, 1473-1490.	3.6	11
50	Optic neuritis: The role of disease-modifying therapy disease-modifying therapy in this clinically isolated syndrome. Current Treatment Options in Neurology, 2007, 9, 48-54.	1.8	0
53	Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b. Journal of Neurology, 2008, 255, 480-487.	3.6	63
54	Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations. Journal of Neurology, 2008, 255, 1449-1463.	3.6	204
55	A three-year, multi-parametric MRI study in patients at presentation with CIS. Journal of Neurology, 2008, 255, 683-691.	3.6	65
56	Rationale for early intervention with immunomodulatory treatments. Journal of Neurology, 2008, 255, 37-43.	3.6	79
57	The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome. Journal of Neurology, 2008, 255, 61-74.	3.6	66
58	Immunomodulatory treatment strategies in multiple sclerosis. Journal of Neurology, 2008, 255, 15-21.	3.6	27
59	Neurotherapeutics in multiple sclerosis: Novel agents and emerging treatment strategies. Mount Sinai Journal of Medicine, 2008, 75, 157-167.	1.9	20
60	Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Acta Neurologica Scandinavica, 2008, 118, 24-28.	2.1	75
61	Diagnosis and treatment of multiple sclerosis. Acta Neurologica Scandinavica, 2008, 117, 12-21.	2.1	38
62	Regulated expression of the interferon-Î² gene in mice. Gene Therapy, 2008, 15, 1-11.	4.5	14

#	ARTICLE	IF	CITATIONS
63	Prospective combined brain and spinal cord MRI in clinically isolated syndromes and possible early multiple sclerosis: impact on dissemination in space and time. <i>European Journal of Neurology</i> , 2008, 15, 1359-1364.	3.3	19
64	Modern multiple sclerosis treatment “ what is approved, what is on the horizon. <i>Drug Discovery Today</i> , 2008, 13, 1013-1025.	6.4	18
65	CSF IgG heavy-chain bias in patients at the time of a clinically isolated syndrome. <i>Journal of Neuroimmunology</i> , 2008, 199, 126-132.	2.3	32
66	Biological response genes after single dose administration of interferon β -1b to healthy male volunteers. <i>Journal of Neuroimmunology</i> , 2008, 199, 115-125.	2.3	15
67	The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2008, 205, 126-134.	2.3	22
68	Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. <i>The Cochrane Library</i> , 2008, , CD005278.	2.8	44
69	New treatment measurements for treatment effects on relapses and progression. <i>Journal of the Neurological Sciences</i> , 2008, 274, 80-83.	0.6	6
70	Pharmacological Treatment of Early Multiple Sclerosis. <i>Drugs</i> , 2008, 68, 73-83.	10.9	41
71	Disease-Modifying Agents for Multiple Sclerosis. <i>Drugs</i> , 2008, 68, 2445-2468.	10.9	63
72	Interferon- β for the treatment of multiple sclerosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 1111-1117.	3.3	6
74	Differential diagnosis of suspected multiple sclerosis: a consensus approach. <i>Multiple Sclerosis Journal</i> , 2008, 14, 1157-1174.	3.0	560
75	Design of Novel Cyclic Altered Peptide Ligands of Myelin Basic Protein MBP ₈₃₋₉₉ That Modulate Immune Responses in SJL/J Mice. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 3971-3978.	6.4	50
76	Management of acute optic neuritis: A survey of neurologists and ophthalmologists in Australia and New Zealand. <i>Journal of Clinical Neuroscience</i> , 2008, 15, 1340-1345.	1.5	9
77	The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. <i>Clinical Neurology and Neurosurgery</i> , 2008, 110, 878-885.	1.4	14
78	Clinical, magnetic resonance imaging, cerebrospinal fluid and electrophysiological characteristics of the earliest multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2008, 110, 233-238.	1.4	22
79	The Clinical Epidemiology of Multiple Sclerosis. <i>Neuroimaging Clinics of North America</i> , 2008, 18, 589-622.	1.0	53
80	Interferon- β -1b. <i>CNS Drugs</i> , 2008, 22, 787-792.	5.9	6
81	Interferon- β treatment for relapsing multiple sclerosis. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1435-1447.	3.1	38

#	ARTICLE	IF	CITATIONS
82	Emerging oral drugs for multiple sclerosis. Expert Opinion on Emerging Drugs, 2008, 13, 465-477.	2.4	17
83	Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nature Clinical Practice Neurology, 2008, 4, 664-675.	2.5	282
84	Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 11839-11844.	7.1	105
85	Interferon-β in Multiple Sclerosis: Effect on Progression of Disability and Clinical Markers of Treatment Response. European Neurology, 2008, 60, 279-284.	1.4	3
86	Gadofluorine M enhancement allows more sensitive detection of inflammatory CNS lesions than T2-w imaging: a quantitative MRI study. Brain, 2008, 131, 2341-2352.	7.6	52
87	Ethics of placebo-controlled clinical trials in multiple sclerosis. Neurology, 2008, 70, 1134-1140.	1.1	65
88	Smoking is a risk factor for early conversion to clinically definite multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 1026-1030.	3.0	113
89	Immunotherapy for clinically isolated syndrome? Not necessarily.... Nature Clinical Practice Neurology, 2008, 4, 236-237.	2.5	2
90	Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain, 2008, 131, 808-817.	7.6	783
91	Early treatment of multiple sclerosis to prevent neurologic damage. Neurology, 2008, 71, S3-7.	1.1	36
92	Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 195-198.	1.9	112
93	Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 114	1.1	114
94	Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 407-414.	1.9	73
95	Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives. Multiple Sclerosis Journal, 2008, 14, 719-727.	3.0	41
96	Current Evidence and Therapeutic Strategies for Multiple Sclerosis. Seminars in Neurology, 2008, 28, 056-068.	1.4	34
98	Déclaration de consensus du Réseau canadien des cliniques de SEP sur: l'utilisation des agents immunomodulateurs dans la sclérose en plaques. Canadian Journal of Neurological Sciences, 2008, 35, 130-132.	0.5	0
99	The Use of Disease-Modifying Agents in Multiple Sclerosis - by the Canadian Network of MS Clinics. Canadian Journal of Neurological Sciences, 2008, 35, 127-129.	0.5	16
100	Management of Optic Neuritis in Canada: Survey of Ophthalmologists and Neurologists. Canadian Journal of Neurological Sciences, 2008, 35, 179-184.	0.5	14

#	ARTICLE	IF	CITATIONS
101	Retinal Nerve Fiber Layer and Future Risk of Multiple Sclerosis. Canadian Journal of Neurological Sciences, 2008, 35, 482-487.	0.5	56
102	Early Interferon Beta Treatment in Multiple Sclerosis. Journal of Neuroscience Nursing, 2008, 40, 356-361.	1.1	9
103	Multiple Sclerosis, Cannabinoids, and Cognition. Journal of Neuropsychiatry and Clinical Neurosciences, 2008, 20, 36-51.	1.8	12
104	Multiple sclerosis therapeutics: opportunities, strategies and challenges. Therapy: Open Access in Clinical Medicine, 2008, 5, 585-587.	0.2	0
105	Acute Inflammatory Demyelinating Optic Neuritis. Neurologist, 2008, 14, 207-223.	0.7	31
106	Multiple sclerosis: new treatment trials and emerging therapeutic targets. Current Opinion in Neurology, 2008, 21, 261-271.	3.6	26
107	Review of the clinical evidence for interferon β 1a (Rebif®) in the treatment of multiple sclerosis. Neuropsychiatric Disease and Treatment, 2008, 4, 321.	2.2	20
108	Review of the Clinical Debate Regarding Interventions for Multiple Sclerosis. Journal of Managed Care Pharmacy, 2009, 15, 1-18.	2.2	3
109	Early stage and long term treatment of multiple sclerosis with interferon-β. Biologics: Targets and Therapy, 2009, , 257.	3.2	6
110	Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. Biologics: Targets and Therapy, 0, , 369.	3.2	3
111	Assessing cost-effectiveness in the management of multiple sclerosis. ClinicoEconomics and Outcomes Research, 2009, 1, 61.	1.9	8
113	Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria. Multiple Sclerosis Journal, 2009, 15, 728-734.	3.0	44
114	Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Multiple Sclerosis Journal, 2009, 15, 1037-1042.	3.0	120
115	Cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 2-8.	3.0	132
116	Association Between Clinical Conversion to Multiple Sclerosis in Radiologically Isolated Syndrome and Magnetic Resonance Imaging, Cerebrospinal Fluid, and Visual Evoked Potential. Archives of Neurology, 2009, 66, 841.	4.5	191
117	We Should Use Magnetic Resonance Imaging to Classify and Monitor the Course of Multiple Sclerosis. Archives of Neurology, 2009, 66, 412-4.	4.5	4
118	Magnetic Resonance Imaging Predictors of Conversion to Multiple Sclerosis in the BENEFIT Study. Archives of Neurology, 2009, 66, 1345-52.	4.5	32
119	Subtraction MR Images in a Multiple Sclerosis Multicenter Clinical Trial Setting. Radiology, 2009, 250, 506-514.	7.3	47

#	ARTICLE	IF	CITATIONS
120	Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit. Multiple Sclerosis Journal, 2009, 15, 951-958.	3.0	17
121	The diagnosis of multiple sclerosis and the clinical subtypes. Annals of Indian Academy of Neurology, 2009, 12, 226.	0.5	54
122	Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis. Neurology, 2009, 73, 46-52.	1.1	137
123	Optimizing Outcomes in Multiple Sclerosis – A Consensus Initiative. Multiple Sclerosis Journal, 2009, 15, 5-35.	3.0	4
124	Disease-modifying agents in multiple sclerosis. Annals of Indian Academy of Neurology, 2009, 12, 273.	0.5	10
125	Interferon- β Treatment in Neuromyelitis Optica. European Neurology, 2009, 62, 167-170.	1.4	70
126	The present efficacy of multiple sclerosis therapeutics. Neurology, 2009, 73, 984-990.	1.1	41
127	Magnetic Resonance Imaging in Multiple Sclerosis. Topics in Magnetic Resonance Imaging, 2009, 20, 313-323.	1.2	5
128	The contribution of cerebrospinal fluid oligoclonal bands to the early diagnosis of multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 472-478.	3.0	31
129	MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome. BMC Neurology, 2009, 9, 19.	1.8	19
130	Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta. Clinical Therapeutics, 2009, 31, 1142-1157.	2.5	42
131	Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurology, The, 2009, 8, 545-559.	10.2	125
132	Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurology, The, 2009, 8, 987-997.	10.2	322
133	Uncertain BENEFIT of early interferon beta-1b treatment. Lancet Neurology, The, 2009, 8, 970-971.	10.2	6
134	Real-life impact of early interferon- β therapy in relapsing multiple sclerosis. Annals of Neurology, 2009, 66, 513-520.	5.3	132
135	Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon β -1b. Neurological Sciences, 2009, 30, 21-31.	1.9	32
136	Treatment of multiple sclerosis: role of natalizumab. Neurological Sciences, 2009, 30, 155-158.	1.9	22
137	Clinically isolated syndrome and multiple sclerosis: Rethinking the arsenal. Current Treatment Options in Neurology, 2009, 11, 193-202.	1.8	7

#	ARTICLE	IF	CITATIONS
138	Human freedom and the brain. Acta Neuropsychiatrica, 2009, 21, 1-6.	2.1	0
139	Multiple sclerosis patients with anti-oligodendrocyte IgM show early favourable response to immunomodulatory treatment. European Journal of Neurology, 2009, 16, 380-385.	3.3	24
140	Early treatment of multiple sclerosis: A Latin American Experts Meeting. Multiple Sclerosis Journal, 2009, 15, 1-12.	3.0	11
141	Multiple sclerosis: an update for oral health care providers. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2009, 108, 318-327.	1.4	21
142	New options for early treatment of multiple sclerosis. Journal of the Neurological Sciences, 2009, 277, S9-S11.	0.6	16
143	Early treatment: PreCISe-ly what the patient needs. Journal of the Neurological Sciences, 2009, 287, S2-S6.	0.6	3
144	Management of optic neuritis and impact of clinical trials: An international survey. Journal of the Neurological Sciences, 2009, 276, 69-74.	0.6	36
145	Differences in retinal nerve fiber layer atrophy between multiple sclerosis subtypes. Journal of the Neurological Sciences, 2009, 281, 74-79.	0.6	95
146	Glatiramer acetate treatment in PPMS: Why males appear to respond favorably. Journal of the Neurological Sciences, 2009, 286, 92-98.	0.6	39
147	Dose response to interferon therapy in multiple sclerosis: an evaluation of the evidence. Current Medical Research and Opinion, 2009, 25, 547-557.	1.9	3
148	A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events. Current Medical Research and Opinion, 2009, 25, 77-92.	1.9	57
149	Optic Neuritis: An Update. II. Optic Neuritis and Multiple Sclerosis. Neuro-Ophthalmology, 2009, 33, 10-22.	1.0	1
150	Review: Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Multiple Sclerosis Journal, 2009, 15, 1175-1182.	3.0	77
151	Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2009, 374, 1503-1511.	13.7	551
152	Treatment of clinically isolated syndrome: to be PreCISe. Lancet, The, 2009, 374, 1475-1476.	13.7	6
153	Influence de la s�miologie de la premi�re pouss�e de scl�rose en plaques sur celle de la deuxi�me. Revue Neurologique, 2009, 165, S11-S13.	1.5	0
155	Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory-demyelinating disease. Multiple Sclerosis Journal, 2009, 15, 918-927.	3.0	80
156	Relapse Management in Multiple Sclerosis. Neurologist, 2009, 15, 1-5.	0.7	43

#	ARTICLE	IF	CITATIONS
157	The Evolving Role of the Nurse in the Treatment of Multiple Sclerosis. Journal of Neuroscience Nursing, 2009, 41, E1-E13.	1.1	8
158	Existing therapies for multiple sclerosis offer proven efficacy and safety. Current Opinion in Neurology, 2009, 22, S4-S9.	3.6	3
159	The Importance of Early Treatment. Journal of Neuroscience Nursing, 2009, 41, E1-E9.	1.1	2
160	Treatment of Multiple Sclerosis. CNS and Neurological Disorders - Drug Targets, 2009, 8, 167-174.	1.4	22
161	Multiple sclerosis: clinical features, pathophysiology, neuroimaging and future therapies. Future Neurology, 2009, 4, 229-246.	0.5	9
163	RETROBULBAR OPTIC NEUROPATHIES. CONTINUUM Lifelong Learning in Neurology, 2009, 15, 47-67.	0.8	1
164	Immunotherapy of multiple sclerosis. Acta Neuropsychiatrica, 2009, 21, 27-34.	2.1	2
165	Increasing the Diagnostic Value of Evoked Potentials in Multiple Sclerosis by Quantitative Topographic Analysis of Multichannel Recordings. Journal of Clinical Neurophysiology, 2009, 26, 316-325.	1.7	11
166	MRI in Multiple Sclerosis. Neuroradiology Journal, 2009, 22, 43-50.	1.2	1
167	Chemotherapeutics in the treatment of multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2010, 3, 277-291.	3.5	28
168	Predicting Conversion to MS - The Role of a History Suggestive of Demyelination. Canadian Journal of Neurological Sciences, 2010, 37, 488-491.	0.5	8
169	PATIENT MANAGEMENT PROBLEM. CONTINUUM Lifelong Learning in Neurology, 2010, 16, 226-233.	0.8	0
170	Recent Developments in the Early Diagnosis and Management of Multiple Sclerosis. Journal of Neuroscience Nursing, 2010, 42, 342-353.	1.1	6
171	CURRENT AND EMERGING MULTIPLE SCLEROSIS THERAPEUTICS. CONTINUUM Lifelong Learning in Neurology, 2010, 16, 58-77.	0.8	6
172	New approaches in the management of multiple sclerosis. Drug Design, Development and Therapy, 2010, 4, 343.	4.3	46
174	The effect of interferon Î²-1a on optic neuritis relapse in patients with multiple sclerosis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248, 231-235.	1.9	2
176	Multiple sclerosis: predicting risk and delaying progression. Lancet Neurology, The, 2010, 9, 7-9.	10.2	5
177	The risk of relapse after a clinically isolated syndrome is related to the pattern of oligoclonal bands. Journal of Neuroimmunology, 2010, 226, 143-146.	2.3	34

#	ARTICLE	IF	CITATIONS
178	Recomendaciones para la utilización e interpretación de los estudios de resonancia magnética en la esclerosis múltiple. <i>Neurología</i> , 2010, 25, 248-265.	0.7	19
180	Decision-making for and impact of early immunomodulatory treatment: the Austrian Clinically Isolated Syndrome Study (ACISS). <i>European Journal of Neurology</i> , 2010, 17, 852-860.	3.3	6
181	Current and future disease-modifying therapies in multiple sclerosis. <i>International Journal of Clinical Practice</i> , 2010, 64, 637-650.	1.7	44
182	The role of glatiramer acetate in the early treatment of multiple sclerosis. <i>Neuropsychiatric Disease and Treatment</i> , 2010, 6, 329.	2.2	4
183	Eye disorders in patients with multiple sclerosis: natural history and management. <i>Clinical Ophthalmology</i> , 2010, 4, 1409.	1.8	51
184	New developments in the treatment of optic neuritis. <i>Eye and Brain</i> , 2010, 2, 83.	2.5	6
185	Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis. <i>Journal of Inflammation Research</i> , 2010, 3, 25.	3.5	13
186	Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes. <i>Multiple Sclerosis Journal</i> , 2010, 16, 62-67.	3.0	144
187	Modifications to the McDonald MRI dissemination in space criteria for use in Asians with classic multiple sclerosis: the Taiwanese experience. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1213-1219.	3.0	7
188	Cross-sectional study assessing long-term safety of interferon-β-1b for relapsing-remitting MS. <i>Neurology</i> , 2010, 74, 1877-1885.	1.1	59
189	A window of opportunity for no treatment in early multiple sclerosis?. <i>Multiple Sclerosis Journal</i> , 2010, 16, 756-759.	3.0	15
190	Compliance with McDonald criteria and red flag recognition in a general neurology practice in Ireland. <i>Multiple Sclerosis Journal</i> , 2010, 16, 678-684.	3.0	4
191	The Onset of Multiple Sclerosis in Greece: A Single-Center Study of 1,034 Consecutive Patients. <i>European Neurology</i> , 2010, 63, 350-356.	1.4	10
192	Should Most Patients With Optic Neuritis be Tested for Neuromyelitis Optica Antibodies and Should This Affect Their Treatment?. <i>Journal of Neuro-Ophthalmology</i> , 2010, 30, 376-379.	0.8	11
193	Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands. <i>Multiple Sclerosis Journal</i> , 2010, 16, 810-815.	3.0	19
194	Clinically isolated syndrome: a protected zone for trials of new therapies?. <i>Multiple Sclerosis Journal</i> , 2010, 16, 754-755.	3.0	4
195	Comparison of multifocal visual evoked potential, standard automated perimetry and optical coherence tomography in assessing visual pathway in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2010, 16, 412-426.	3.0	54
196	Single-Nucleotide Polymorphisms in Response to Interferon-Beta Therapy in Multiple Sclerosis. <i>Journal of Interferon and Cytokine Research</i> , 2010, 30, 727-732.	1.2	13

#	ARTICLE	IF	CITATIONS
197	Update on the treatment options for multiple sclerosis. Expert Review of Clinical Immunology, 2010, 6, 77-88.	3.0	13
198	Multiple Sclerosis. Journal of Pharmacy Practice, 2010, 23, 91-100.	1.0	7
199	Accuracy of MRI criteria for dissemination in space for the diagnosis of multiple sclerosis in patients with clinically isolated syndromes. Multiple Sclerosis Journal, 2010, 16, 576-580.	3.0	10
200	MR Imaging in Multiple Sclerosis: Review and Recommendations for Current Practice. American Journal of Neuroradiology, 2010, 31, 983-989.	2.4	91
201	Interferon-beta Inhibits Th17 Cell Differentiation in Patients with Multiple Sclerosis. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2010, 10, 161-167.	1.2	21
202	Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?. Multiple Sclerosis Journal, 2010, 16, 862-867.	3.0	46
203	A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsingâ€”remitting multiple sclerosis (TIME MS). Therapeutic Advances in Neurological Disorders, 2010, 3, 3-13.	3.5	24
204	Evolving expectations around early management of multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2010, 3, 351-367.	3.5	81
205	Magnetic resonance imaging and treatment effects of multiple sclerosis therapeutics. Neurology, 2010, 74, S54-61.	1.1	11
206	Optic Neuritis. Neurologic Clinics, 2010, 28, 573-580.	1.8	7
207	Good results for early treatment of clinically isolated syndrome prior to multiple sclerosis with interferon beta-1b and glatiramer group. Expert Opinion on Pharmacotherapy, 2010, 11, 1225-1230.	1.8	8
208	Recommendations for using and interpreting magnetic resonance imaging in multiple sclerosis. NeurologÃa (English Edition), 2010, 25, 248-265.	0.4	8
209	Spanish Neurology Society consensus document on the use of drugs in multiple sclerosis: Escalating therapy. NeurologÃa (English Edition), 2010, 25, 378-390.	0.4	8
211	Meeting Review: The management of multiple sclerosis in children: a European view. Multiple Sclerosis Journal, 2010, 16, 1258-1267.	3.0	91
213	Therapy of MS. Clinical Neurology and Neurosurgery, 2010, 112, 365-385.	1.4	85
214	Animal models of multiple sclerosisâ€”Potentials and limitations. Progress in Neurobiology, 2010, 92, 386-404.	5.7	182
216	Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 643-660.	3.3	18
217	Therapeutic strategies in childhood multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2010, 3, 217-228.	3.5	21

#	ARTICLE	IF	CITATIONS
218	Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. <i>Neurology</i> , 2011, 76, S14-25.	1.1	83
219	A Comparison of Optic Neuritis in Asian and in Western Countries. <i>Neuro-Ophthalmology</i> , 2011, 35, 65-72.	1.0	19
220	MRI only conversion to multiple sclerosis following a clinically isolated syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 176-179.	1.9	44
221	Natural History of Multiple Sclerosis: Early Prognostic Factors. <i>Neurologic Clinics</i> , 2011, 29, 279-292.	1.8	27
222	Natural History of Multiple Sclerosis: Have Available Therapies Impacted Long-Term Prognosis?. <i>Neurologic Clinics</i> , 2011, 29, 309-321.	1.8	32
223	FDA-Approved Preventative Therapies for MS: First-line Agents. <i>Neurologic Clinics</i> , 2011, 29, 401-409.	1.8	5
224	Meeting Highlights on Psychiatric Treatment Perspectives in Neurology: The 3rd Annual Chair Summit. <i>Health Outcomes Research in Medicine</i> , 2011, 2, e183-e194.	0.6	0
225	Early treatment in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2011, 311, S24-S28.	0.6	10
226	Interferon- β -1b. <i>CNS Drugs</i> , 2011, 25, 67-88.	5.9	66
227	The Mechanism of Action of Interferon- β in Relapsing Multiple Sclerosis. <i>CNS Drugs</i> , 2011, 25, 491-502.	5.9	257
228	Subcutaneous Recombinant Interferon- β -1a (Rebif®). <i>Drugs</i> , 2011, 71, 1865-1891.	10.9	22
229	Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients. <i>Multiple Sclerosis Journal</i> , 2011, 17, 353-360.	3.0	17
230	Clinical Neuroimmunology. , 2011, , .		0
231	Magnetic Resonance Imaging in Multiple Sclerosis: The Role of Conventional Imaging. <i>Neurologic Clinics</i> , 2011, 29, 343-356.	1.8	14
232	Injection of interferon-beta in the morning decreases flu-like syndrome in many patients with multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2011, 113, 316-322.	1.4	26
233	Clinical outcome of relapsing remitting multiple sclerosis among Hong Kong Chinese. <i>Clinical Neurology and Neurosurgery</i> , 2011, 113, 617-622.	1.4	15
234	Esclerosis múltiple. Criterios diagnósticos y pruebas complementarias. <i>Medicine</i> , 2011, 10, 5087-5093.	0.0	0
235	Tratamiento de la esclerosis múltiple. <i>Medicine</i> , 2011, 10, 5094-5100.	0.0	0

#	ARTICLE	IF	CITATIONS
236	Protocolo diagnóstico del paciente con sospecha de enfermedad desmielinizante. Medicine, 2011, 10, 5109-5111.	0.0	0
237	Ethical considerations in multiple sclerosis clinical trials. , 0, , 261-271.		0
238	Measures of acute and chronic lesions visualized by conventional magnetic resonance imaging. , 2011, , 91-111.		0
240	The challenge of demonstrating long-term benefit of disease-modifying therapies in multiple sclerosis. , 0, , 244-252.		2
242	Use of MRI in the clinical management of multiple sclerosis. , 0, , 645-653.		0
244	Development of oral immunomodulatory agents in the management of multiple sclerosis. Drug Design, Development and Therapy, 2011, 5, 255.	4.3	29
245	Exploring the Association between Retinal Nerve Fiber Layer Thickness and Initial Magnetic Resonance Imaging Findings in Patients with Acute Optic Neuritis. Multiple Sclerosis International, 2011, 2011, 1-6.	0.8	10
246	When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?. Multiple Sclerosis International, 2011, 2011, 1-11.	0.8	5
247	Establishing Long-Term Efficacy in Chronic Disease: Use of Recursive Partitioning and Propensity Score Adjustment to Estimate Outcome in MS. PLoS ONE, 2011, 6, e22444.	2.5	34
248	Multiple sclerosis: current treatment algorithms. Current Opinion in Neurology, 2011, 24, 230-237.	3.6	65
250	Accuracy of diagnostic tests in multiple sclerosis - a systematic review. Acta Neurologica Scandinavica, 2011, 124, 151-164.	2.1	37
251	Potential Health Care Cost Savings Associated With Early Treatment of Multiple Sclerosis Using Disease-Modifying Therapy. Clinical Therapeutics, 2011, 33, 914-925.	2.5	25
252	Current Disease-Modifying Treatment of Multiple Sclerosis. Mount Sinai Journal of Medicine, 2011, 78, 161-175.	1.9	55
253	Exacerbation history is associated with medication and appointment adherence in MS. Journal of Behavioral Medicine, 2011, 34, 330-338.	2.1	15
254	Neutralizing antibodies in interferon beta treated patients with multiple sclerosis: knowing what to do now. Journal of Neurology, 2011, 258, 904-907.	3.6	4
255	Managing MS in a changing treatment landscape. Journal of Neurology, 2011, 258, 728-739.	3.6	29
256	Treatment of multiple sclerosis: current concepts and future perspectives. Journal of Neurology, 2011, 258, 1747-1762.	3.6	47
257	Head tremor secondary to MS resolved with rituximab. Neurological Sciences, 2011, 32, 1157-1160.	1.9	4

#	ARTICLE	IF	CITATIONS
258	Fulminant multiple sclerosis (MS). <i>Neurological Sciences</i> , 2011, 32, 953-957.	1.9	10
259	The Radiologically Isolated Syndrome: Look (Again) Before You Treat. <i>Current Neurology and Neuroscience Reports</i> , 2011, 11, 498-506.	4.2	15
260	Alternative statistical methods for estimating efficacy of interferon beta-1b for multiple sclerosis clinical trials. <i>BMC Medical Research Methodology</i> , 2011, 11, 80.	3.1	11
261	No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset. <i>Annals of Neurology</i> , 2011, 69, 90-99.	5.3	155
262	Optimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America. <i>Therapeutic Advances in Neurological Disorders</i> , 2011, 4, 349-360.	3.5	14
264	Prognostic value of cerebrospinal fluid analysis at the time of a first demyelinating event. <i>Multiple Sclerosis Journal</i> , 2011, 17, 164-172.	3.0	14
265	Economic Burden in a German Cohort of Patients with Multiple Sclerosis. <i>European Neurology</i> , 2011, 66, 311-321.	1.4	31
267	Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsingâ€“remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1504-1513.	3.0	7
268	Principles of a new treatment algorithm in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 351-362.	2.8	23
269	Interferon Î²-1bâ€“neutralizing antibodies 5 years after clinically isolated syndrome. <i>Neurology</i> , 2011, 77, 835-843.	1.1	44
270	Management of optic neuritis. <i>Indian Journal of Ophthalmology</i> , 2011, 59, 117.	1.1	34
271	Sun exposure and vitamin D are independent risk factors for CNS demyelination. <i>Neurology</i> , 2011, 76, 540-548.	1.1	324
272	No increase in cancer incidence detected after cyclophosphamide in a French cohort of patients with progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 55-63.	3.0	12
273	Optic neuritis: A blurry issue. <i>Neurology India</i> , 2012, 60, 459.	0.4	1
274	Predictive nature of IgM anti-Î±-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 966-973.	3.0	13
275	Effect of disease-modifying drugs on cortical lesions and atrophy in relapsingâ€“remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 418-424.	3.0	69
276	Early Diagnosis, Monitoring, and Treatment of Optic Neuritis. <i>Neurologist</i> , 2012, 18, 23-31.	0.7	11
277	The neuro-ophthalmology of multiple sclerosis. <i>Future Neurology</i> , 2012, 7, 679-700.	0.5	4

#	ARTICLE	IF	CITATIONS
278	Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review. Multiple Sclerosis Journal, 2012, 18, 1705-1717.	3.0	55
279	Application of the 2010 McDonald criteria for the diagnosis of multiple sclerosis in a Spanish cohort of patients with clinically isolated syndromes. Multiple Sclerosis Journal, 2012, 18, 39-44.	3.0	37
280	Reliability and equivalence of alternate forms for the Symbol Digit Modalities Test: implications for multiple sclerosis clinical trials. Multiple Sclerosis Journal, 2012, 18, 1320-1325.	3.0	103
281	Do not treat from CIS onset: evaluate disease course and prognosis first - Commentary. Multiple Sclerosis Journal, 2012, 18, 396-397.	3.0	4
282	Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1466-1471.	3.0	58
283	Management of optic neuritis as a clinically first event of multiple sclerosis. Current Opinion in Ophthalmology, 2012, 23, 472-476.	2.9	14
284	Current and Emerging Therapies for the Treatment of Multiple Sclerosis: Focus on Cladribine. Journal of Central Nervous System Disease, 2012, 4, JCNSD.S5128.	1.9	4
285	Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis. Current Pharmaceutical Design, 2012, 18, 4513-4517.	1.9	2
288	Placebo-controlled trials in relapsing-remitting multiple sclerosis: are they still needed?. Future Neurology, 2012, 7, 37-44.	0.5	0
290	Disease-modifying drugs in multiple sclerosis: new oral options. Clinical Practice (London, England), 2012, 9, 315-327.	0.1	0
291	Fingolimod for Multiple Sclerosis. New England Journal of Medicine, 2012, 366, 339-347.	27.0	277
292	Detecting multiple sclerosis mimics early. Future Neurology, 2012, 7, 547-555.	0.5	3
293	Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment. Journal of Neurology, 2012, 259, 2347-2353.	3.6	11
294	Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group. Wiener Medizinische Wochenschrift, 2012, 162, 354-366.	1.1	16
295	Les traitements de première ligne dans la sclérose en plaques. Pratique Neurologique - FMC, 2012, 3, 73-89.	0.1	0
296	Immunotherapies in Neurologic Disorders. Medical Clinics of North America, 2012, 96, 497-523.	2.5	7
297	Treatment of cognitive impairment in patients with multiple sclerosis. Expert Opinion on Investigational Drugs, 2012, 21, 1679-1699.	4.1	26
298	Association Between Immediate Initiation of Intramuscular Interferon Beta-1a at the Time of a Clinically Isolated Syndrome and Long-term Outcomes. Archives of Neurology, 2012, 69, 183.	4.5	92

#	ARTICLE	IF	CITATIONS
299	Handbook of Multiple Sclerosis. , 2012, , .		9
301	Current and emerging therapies in multiple sclerosis: a systematic review. Therapeutic Advances in Neurological Disorders, 2012, 5, 205-220.	3.5	112
302	Neuropsychiatric Dysfunction in Multiple Sclerosis. , 2012, , .		8
306	Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis. Journal of Central Nervous System Disease, 2012, 4, JCNSD.S8755.	1.9	3
307	Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis?. Neuropsychiatric Disease and Treatment, 2012, 8, 465.	2.2	4
308	Shifting imaging targets in multiple sclerosis: From inflammation to neurodegeneration. Journal of Magnetic Resonance Imaging, 2012, 36, 1-19.	3.4	52
309	Cost-Effectiveness Analysis of Interferon Beta-1b for the Treatment of Patients With a First Clinical Event Suggestive of Multiple Sclerosis. Clinical Therapeutics, 2012, 34, 1132-1144.	2.5	13
310	Depressive episode characteristics and subsequent recurrence risk. Journal of Affective Disorders, 2012, 140, 277-284.	4.1	22
311	Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurology, The, 2012, 11, 33-41.	10.2	185
312	Clinically isolated syndromes. Lancet Neurology, The, 2012, 11, 157-169.	10.2	398
313	The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics. Multiple Sclerosis and Related Disorders, 2012, 1, 81-86.	2.0	40
314	Treatment of Pediatric Optic Neuritis. Current Treatment Options in Neurology, 2012, 14, 93-102.	1.8	22
315	Multiple Sclerosis and the Spinal Cord. Neurologic Clinics, 2013, 31, 55-77.	1.8	7
316	Predictors of quality of life among multiple sclerosis patients: a comprehensive analysis. European Journal of Neurology, 2013, 20, 756-764.	3.3	94
317	Efficacy and safety of interferon beta-1b sc in older RRMS patients"a posthoc analysis of the BEYOND study. Journal of Neurology, 2013, 260, 1838-1845.	3.6	9
318	Treatment of cognitive impairment in multiple sclerosis: position paper. Journal of Neurology, 2013, 260, 1452-1468.	3.6	189
319	Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study. Journal of Neurology, 2013, 260, 1583-1593.	3.6	29
320	Multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 110, 461-470.	1.8	1

#	ARTICLE	IF	CITATIONS
322	Cambios e implicaciones en la aplicaci3n de la revisi3n de criterios de McDonald 2010 en los s3ndromes cl3nicamente aislados. Neurologia Argentina, 2013, 5, 70-77.	0.3	0
323	Updates on Clinically Isolated Syndrome and Diagnostic Criteria for Multiple Sclerosis. Neurohospitalist, The, 2013, 3, 65-80.	0.8	35
324	Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with Clinically Isolated Syndrome. Journal of Neuroimmunology, 2013, 257, 76-81.	2.3	53
325	Using biomarkers to predict progression from clinically isolated syndrome to multiple sclerosis. Journal of Clinical Bioinformatics, 2013, 3, 18.	1.2	9
326	Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis. BMC Neurology, 2013, 13, 180.	1.8	24
327	Consensus statement on medication use in multiple sclerosis by the Spanish Society of Neurology's study group for demyelinating diseases. Neurolog3a (English Edition), 2013, 28, 375-378.	0.4	8
328	The cost burden of multiple sclerosis in the United States: a systematic review of the literature. Journal of Medical Economics, 2013, 16, 639-647.	2.1	175
329	An approach to optic neuritis: the initial presentation. Expert Review of Ophthalmology, 2013, 8, 539-551.	0.6	4
330	Interferon Beta and Glatiramer Acetate Therapy. Neurotherapeutics, 2013, 10, 2-18.	4.4	53
331	Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: A3brief overview. European Journal of Medicinal Chemistry, 2013, 60, 170-186.	5.5	29
332	Documento del Grupo de Consenso de la Sociedad Espa3ola de Neurolog3a sobre el uso de medicamentos en esclerosis m3ltiple. Neurolog3a, 2013, 28, 375-378.	0.7	18
333	Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis. European Journal of Paediatric Neurology, 2013, 17, 50-54.	1.6	45
334	Immunotherapy of Multiple Sclerosis. BioDrugs, 2013, 27, 113-148.	4.6	23
335	Learning and cognitive fatigue trajectories in multiple sclerosis defined using a burst measurement design. Multiple Sclerosis Journal, 2013, 19, 1518-1525.	3.0	16
336	A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	8.0	7
337	Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. Neurology, 2013, 80, 234-241.	1.1	53
338	The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nature Reviews Neurology, 2013, 9, 267-276.	10.1	181
339	Update on immunopathogenesis and immunotherapy in multiple sclerosis. ImmunoTargets and Therapy, 2013, 2, 21.	5.8	17

#	ARTICLE	IF	CITATIONS
340	Consensus guidelines for the diagnosis and treatment of multiple sclerosis. Current Medical Research and Opinion, 2013, 29, 611-621.	1.9	21
341	The Usefulness of Gadolinium-Enhanced Images on a Follow-up Magnetic Resonance Image in Suspected Multiple Sclerosis. Canadian Association of Radiologists Journal, 2013, 64, 358-362.	2.0	1
342	Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. The Cochrane Library, 2013, , CD008933.	2.8	109
343	Drugs in Development for Relapsing Multiple Sclerosis. Drugs, 2013, 73, 625-650.	10.9	53
344	Subcutaneous Interferon Beta-1a in Pediatric Multiple Sclerosis. Journal of Child Neurology, 2013, 28, 849-856.	1.4	65
345	Costo-efectividad del tratamiento con interferón beta en pacientes con síndrome clínico aislado de alto riesgo en Colombia. Biomedica, 2013, 34, 110.	0.7	1
346	Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Multiple Sclerosis Journal, 2013, 19, 765-774.	3.0	66
347	Autoinjectors for administration of interferon beta-1b in multiple sclerosis: patient preferences and the ExtaviPro®; 30G and Betacomfort®; devices. Journal of Pragmatic and Observational Research, 2013, 4, 19.	1.5	7
349	29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis in Copenhagen. Clinical and Experimental Neuroimmunology, 2013, 4, 358-362.	1.0	0
350	Time to first relapse as an endpoint in multiple sclerosis clinical trials. Multiple Sclerosis Journal, 2013, 19, 466-474.	3.0	27
351	Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations. Canadian Journal of Neurological Sciences, 2013, 40, 307-323.	0.5	178
352	Evidence for Long-Term Use of Intramuscular Interferon Beta-1a: An Overview of Relapse, Disability, and MRI Data from Selected Clinical Trials. Journal of Managed Care Pharmacy, 2013, 19, S04-S15.	2.2	2
353	Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta. Neuropsychiatric Disease and Treatment, 2013, 9, 1339.	2.2	14
354	Intramuscular Interferon Beta-1a and Evolving Treatment Options and Outcomes Measurement for MS: Considerations for Managed Care. Journal of Managed Care Pharmacy, 2013, 19, 1-53.	2.2	0
355	Extaviject®; 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study. Medical Devices: Evidence and Research, 2013, 6, 175.	0.8	12
356	Perspectives for Managed Care Organizations on the Burden of Multiple Sclerosis and the Cost-Benefits of Disease-Modifying Therapies. Journal of Managed Care Pharmacy, 2013, 19, S41-S53.	2.2	41
357	Presence and Significant Determinants of Cognitive Impairment in a Large Sample of Patients with Multiple Sclerosis. PLoS ONE, 2013, 8, e69820.	2.5	44
358	Which Immune Cells Matter? The Immunopathogenesis of Multiple Sclerosis. Critical Reviews in Immunology, 2013, 33, 283-306.	0.5	35

#	ARTICLE	IF	CITATIONS
359	Identifying responders and nonresponders to interferon therapy in multiple sclerosis. Degenerative Neurological and Neuromuscular Disease, 2014, 4, 75.	1.3	6
360	Direct and Indirect Economic Consequences of Multiple Sclerosis in Ireland. Applied Health Economics and Health Policy, 2014, 12, 635-645.	2.1	25
361	Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1183-1189.	1.9	73
362	Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome. Therapeutic Advances in Neurological Disorders, 2014, 7, 279-288.	3.5	10
363	Efficacy and safety of subcutaneous interferon- β -1a in patients with a first demyelinating event and early multiple sclerosis. Expert Opinion on Biological Therapy, 2014, 14, 1207-1214.	3.1	4
364	Immune responses of linear and cyclic PLP ₁₃₉₋₁₅₁ mutant peptides in SJL/J mice: peptides in their free state versus mannan conjugation. Immunotherapy, 2014, 6, 709-724.	2.0	11
365	Fostering adherence to injectable disease-modifying therapies in multiple sclerosis. Expert Review of Neurotherapeutics, 2014, 14, 1029-1042.	2.8	52
366	Assessing treatment response to interferon- β . Neurology, 2014, 82, 248-254.	1.1	61
368	Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. Multiple Sclerosis Journal, 2014, 20, 234-242.	3.0	19
369	Successful twin delivery after a radical trachelectomy. Journal of Obstetrics and Gynaecology, 2014, 34, 87-87.	0.9	3
371	Understanding the role of gender and hormones in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 518-519.	3.0	1
372	Early MRI activity predicts treatment nonresponse with intramuscular interferon beta-1a in clinically isolated syndrome. Multiple Sclerosis and Related Disorders, 2014, 3, 712-719.	2.0	7
373	Multiple sclerosis treatment and infectious issues: update 2013. Clinical and Experimental Immunology, 2014, 175, 425-438.	2.6	32
374	Cell therapy for multiple sclerosis: a new hope. Bioscience Horizons, 2014, 7, hzu014-hzu014.	0.6	2
375	New management algorithms in multiple sclerosis. Current Opinion in Neurology, 2014, 27, 246-259.	3.6	95
378	Outcome Measures in Relapsing-Remitting Multiple Sclerosis: Capturing Disability and Disease Progression in Clinical Trials. Multiple Sclerosis International, 2014, 2014, 1-13.	0.8	53
379	Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. Multiple Sclerosis and Related Disorders, 2014, 3, 147-155.	2.0	57
380	Short-term and long-term safety and tolerability of interferon β -1b in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2014, 3, 294-302.	2.0	37

#	ARTICLE	IF	CITATIONS
381	Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon- β therapy. <i>European Journal of Neurology</i> , 2014, 21, 377.	3.3	23
382	New treatments for multiple sclerosis: at what long-term risk?. <i>Lancet Neurology</i> , The, 2014, 13, 235-237.	10.2	1
383	Individualizing therapy for multiple sclerosis: a focus on disease-modifying drugs. <i>Clinical Practice</i> (London, England), 2014, 11, 105-115.	0.1	0
384	Optic neuritis. <i>Lancet Neurology</i> , The, 2014, 13, 83-99.	10.2	463
385	Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies. <i>Clinical and Experimental Immunology</i> , 2014, 175, 359-372.	2.6	38
386	Risk of multiple sclerosis after optic neuritis in patients with normal baseline brain MRI. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 583-586.	1.5	25
387	Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression. <i>JAMA Neurology</i> , 2014, 71, 306.	9.0	402
388	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1835-1846.	1.5	15
389	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1847-1856.	1.5	22
390	Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis. <i>Advances in Therapy</i> , 2014, 31, 915-931.	2.9	32
391	Molecular mechanism underlying the impact of vitamin D on disease activity of MS. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 605-617.	3.7	44
392	IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: Current and future developments. <i>Cytokine and Growth Factor Reviews</i> , 2014, 25, 403-413.	7.2	107
393	Drug therapy for multiple sclerosis. <i>Cmaj</i> , 2014, 186, 833-840.	2.0	17
394	Update on Disease-Modifying Treatments for Multiple Sclerosis. <i>Clinical Therapeutics</i> , 2014, 36, 1938-1945.	2.5	45
395	Early prognosis of multiple sclerosis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 122, 371-391.	1.8	15
396	Clinically isolated syndromes and the relationship to multiple sclerosis. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 2065-2071.	1.5	61
397	Diagnosis and trials of clinically isolated syndrome. <i>Lancet Neurology</i> , The, 2014, 13, 962-963.	10.2	3
398	Disease-modifying agents in multiple sclerosis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 122, 465-501.	1.8	10

#	ARTICLE	IF	CITATIONS
399	A changing treatment landscape for multiple sclerosis: challenges and opportunities. Journal of Internal Medicine, 2014, 275, 364-381.	6.0	50
400	The clinical course of multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 343-369.	1.8	126
401	Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clinical and Experimental Immunology, 2014, 175, 397-407.	2.6	68
402	Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2014, 13, 977-986.	10.2	254
403	Clinically isolated syndrome in pregnancy. Journal of Obstetrics and Gynaecology, 2014, 34, 86-86.	0.9	0
404	Defining the clinical course of multiple sclerosis. Neurology, 2014, 83, 278-286.	1.1	2,344
405	A web-based decision support tool for prognosis simulation in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2014, 3, 575-583.	2.0	4
406	Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurology, The, 2014, 13, 257-267.	10.2	194
407	Emergency Department visits before the diagnosis of MS. Multiple Sclerosis and Related Disorders, 2014, 3, 350-354.	2.0	12
408	The STAR Study: A Real-World, International, Observational Study of the Safety and Tolerability of, and Adherence to, Serum-Free Subcutaneous Interferon β -1a in Patients With Relapsing Multiple Sclerosis. Clinical Therapeutics, 2014, 36, 1946-1957.	2.5	24
409	Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies. Mayo Clinic Proceedings, 2014, 89, 225-240.	3.0	364
410	Mode of action and clinical studies with fumarates in multiple sclerosis. Experimental Neurology, 2014, 262, 52-56.	4.1	27
411	Predictive markers of disease evolution after a CIS in everyday practice. Journal of the Neurological Sciences, 2014, 343, 8-14.	0.6	4
412	Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event. PLoS ONE, 2014, 9, e90509.	2.5	254
416	Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis. Therapeutics and Clinical Risk Management, 2015, 11, 759.	2.0	10
417	Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?. World Journal of Clinical Cases, 2015, 3, 545.	0.8	190
418	Diagnosis Approach of Optic Neuritis. Journal of Neurology & Neurophysiology, 2015, 06, .	0.1	2
419	Consensus recommendations for the diagnosis and treatment of multiple sclerosis: the Middle East North Africa Committee for Treatment and Research In Multiple Sclerosis (MENACTRIMS). Current Medical Research and Opinion, 2015, 31, 1349-1361.	1.9	29

#	ARTICLE	IF	CITATIONS
420	Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis. <i>Drugs</i> , 2015, 75, 947-977.	10.9	31
421	Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 659-673.	1.8	21
422	Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. <i>Practical Neurology</i> , 2015, 15, 273-279.	1.1	169
423	Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β 1a. <i>European Journal of Neurology</i> , 2015, 22, 1113-1123.	3.3	25
424	Predictors of disability worsening in clinically isolated syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 479-491.	3.7	43
425	IL-11 Induces Th17 Cell Responses in Patients with Early Relapsing-Remitting Multiple Sclerosis. <i>Journal of Immunology</i> , 2015, 194, 5139-5149.	0.8	49
426	Defining high, medium and low impact prognostic factors for developing multiple sclerosis. <i>Brain</i> , 2015, 138, 1863-1874.	7.6	403
428	Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and Monitoring. <i>Canadian Journal of Neurological Sciences</i> , 2015, 42, 159-167.	0.5	20
429	Acceptance of the Extracare Program by Beta Interferon-Treated Patients With Multiple Sclerosis. <i>Journal of Neuroscience Nursing</i> , 2015, 47, E31-E39.	1.1	7
430	Update on clinically isolated syndrome. <i>Presse Medicale</i> , 2015, 44, e121-e136.	1.9	11
431	Update on treatments in multiple sclerosis. <i>Presse Medicale</i> , 2015, 44, e137-e151.	1.9	32
432	Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis. <i>CNS Drugs</i> , 2015, 29, 759-771.	5.9	16
433	Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. <i>Journal of Neurology</i> , 2015, 262, 2466-2471.	3.6	4
434	Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon- β 2. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1803-1819.	3.3	22
435	No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. <i>Neurology</i> , 2015, 85, 1694-1701.	1.1	55
436	The effect of disease-modifying therapies on brain atrophy in patients with clinically isolated syndrome: a systematic review and meta-analysis. <i>Therapeutic Advances in Neurological Disorders</i> , 2015, 8, 193-202.	3.5	24
437	Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2015, 8, 212-232.	3.5	20
439	Safety and efficacy of fingolimod in clinical practice: The experience of an academic center in the Middle East. <i>Journal of Neuroimmunology</i> , 2015, 289, 93-97.	2.3	24

#	ARTICLE	IF	CITATIONS
440	Is TOPIC the last trial for clinically isolated syndrome?. Nature Reviews Neurology, 2015, 11, 6-7.	10.1	1
441	Selected Extracellular microRNA as Potential Biomarkers of Multiple Sclerosis Activityâ€”Preliminary Study. Journal of Molecular Neuroscience, 2015, 56, 154-163.	2.3	42
442	IFN-Î² and multiple sclerosis: From etiology to therapy and back. Cytokine and Growth Factor Reviews, 2015, 26, 221-228.	7.2	28
443	Treatment of Acute Optic Neuritis and Vision Complaints in Multiple Sclerosis. Current Treatment Options in Neurology, 2015, 17, 328.	1.8	6
444	Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsingâ€”remitting multiple sclerosis (RRMS). Multiple Sclerosis Journal, 2015, 21, 57-66.	3.0	56
445	Ten-year follow-up of the â€œminimal MRI lesionâ€™ subgroup from the original CHAMPS Multiple Sclerosis Prevention Trial. Multiple Sclerosis Journal, 2015, 21, 415-422.	3.0	10
446	The Prognostic Utility of MRI in Clinically Isolated Syndrome: A Literature Review. American Journal of Neuroradiology, 2015, 36, 425-431.	2.4	15
448	Multiple Sclerosis Subtypes. , 2016, , 55-65.		0
449	McDonald Criteria 2010 and 2005 Compared: Persistence of High Oligoclonal Band Prevalence Despite Almost Doubled Diagnostic Sensitivity. International Journal of Molecular Sciences, 2016, 17, 1592.	4.1	34
450	Interferon Î² in Multiple Sclerosis. , 2016, , 191-201.		5
451	Clinically Isolated Syndromes: Clinical Characteristics, Differential Diagnosis, and Management. Noropsikiyatri Arsivi, 2016, 52, 1-11.	0.7	15
452	Optic neuritis as an early sign of multiple sclerosis. Eye and Brain, 2016, Volume 8, 195-202.	2.5	94
453	MRI and neurophysiological measures to predict course, disability and treatment response in multiple sclerosis. Current Opinion in Neurology, 2016, 29, 243-253.	3.6	29
454	Brain health: time matters in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 9, S5-S48.	2.0	280
455	Update on monitoring and adverse effects of first generation disease modifying therapies and their recently approved versions in relapsing forms of multiple sclerosis. Current Opinion in Neurology, 2016, 29, 272-277.	3.6	9
457	Risk factors for conversion to clinically defined multiple sclerosis after clinically isolated syndrome in a racially mixed Brazilian cohort. Clinical Neurology and Neurosurgery, 2016, 146, 40-44.	1.4	5
458	Balancing Early Aggression Against Risk of Progression in Multiple Sclerosis. Canadian Journal of Neurological Sciences, 2016, 43, 33-43.	0.5	13
459	Prognostic factors associated with long-term disability and secondary progression in patients with Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2016, 8, 27-34.	2.0	17

#	ARTICLE	IF	CITATIONS
460	Variations in multiple sclerosis practice within Europe – Is it time for a new treatment guideline?. Multiple Sclerosis and Related Disorders, 2016, 8, 35-44.	2.0	23
461	Rethinking the importance of paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis: They do matter. Multiple Sclerosis and Related Disorders, 2016, 9, 150-154.	2.0	11
462	Does early (treatment in) BENEFIT lead to late MS benefit?. Neurology, 2016, 87, 970-971.	1.1	0
463	The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology, 2016, 87, 978-987.	1.1	109
464	Disease-modifying treatments for multiple sclerosis – a review of approved medications. European Journal of Neurology, 2016, 23, 18-27.	3.3	238
465	Pediatric multiple sclerosis. Neurology, 2016, 87, S97-S102.	1.1	67
466	Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT [®]) With Mechanical Autoinjectors. Neurology and Therapy, 2016, 5, 155-167.	3.2	14
467	Disease modifying therapies for relapsing multiple sclerosis. BMJ, The, 2016, 354, i3518.	6.0	127
468	Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain. Neurología (English Edition), 2016, 31, 247-254.	0.4	0
469	Placebo-controlled study in neuromyelitis optica – Ethical and design considerations. Multiple Sclerosis Journal, 2016, 22, 862-872.	3.0	63
470	Glatiramer acetate during early pregnancy: A prospective cohort study. Multiple Sclerosis Journal, 2016, 22, 810-816.	3.0	79
472	Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis. CNS Drugs, 2016, 30, 209-225.	5.9	23
473	Consensus recommendations for the diagnosis and treatment of multiple sclerosis in Kuwait. Clinical Neurology and Neurosurgery, 2016, 143, 51-64.	1.4	3
474	Interferon-beta exposure during first trimester is safe in women with multiple sclerosis – A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Multiple Sclerosis Journal, 2016, 22, 801-809.	3.0	102
475	Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies. Neurology and Therapy, 2016, 5, 45-57.	3.2	33
477	Immunomodulatory therapies delay disease progression in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1732-1740.	3.0	48
478	Soluble CD27 Levels in Cerebrospinal Fluid as a Prognostic Biomarker in Clinically Isolated Syndrome. JAMA Neurology, 2017, 74, 286.	9.0	27
479	Subcutaneous interferon β -1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 285-294.	1.9	38

#	ARTICLE	IF	CITATIONS
480	Assessment and Diagnosis of Relapsing Multiple Sclerosis. , 2017, , 41-66.		0
481	Radiologically isolated syndrome and clinically isolated syndrome. Clinical and Experimental Neuroimmunology, 2017, 8, 24-32.	1.0	6
482	Multiple Sclerosis: An Overview. , 2017, , 1-16.		2
483	Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study. Journal of Neurology, 2017, 264, 1068-1075.	3.6	25
484	Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. The Cochrane Library, 2017, 4, CD012200.	2.8	20
485	Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 1â€”Mechanisms, Efficacy, and Safety. American Journal of Neuroradiology, 2017, 38, 1664-1671.	2.4	8
486	Prognostic indicators in pediatric clinically isolated syndrome. Annals of Neurology, 2017, 81, 729-739.	5.3	34
487	Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar. Current Medical Research and Opinion, 2017, 33, 439-458.	1.9	6
488	Citation classics in central nervous system inflammatory demyelinating disease. Brain and Behavior, 2017, 7, e00700.	2.2	5
489	Sodium intake and multiple sclerosis activity and progression in <scp>BENEFIT</scp>. Annals of Neurology, 2017, 82, 20-29.	5.3	80
490	Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 2122-2133.	27.0	153
491	Multiple Sclerosis. Neuroimaging Clinics of North America, 2017, 27, 195-204.	1.0	51
492	The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. Journal of Neurology, 2017, 264, 453-466.	3.6	105
493	Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials. Neurotherapeutics, 2017, 14, 934-944.	4.4	52
494	Systematic review of depression in patients with multiple sclerosis and its relationship to interferonÎ² treatment. Multiple Sclerosis and Related Disorders, 2017, 17, 138-143.	2.0	36
495	Multiple Sclerosis: Basic and Clinical. Advances in Neurobiology, 2017, 15, 211-252.	1.8	7
497	Disease modifying treatments and symptomatic drugs for cognitive impairment in multiple sclerosis: where do we stand?. Multiple Sclerosis and Demyelinating Disorders, 2017, 2, .	1.1	7
498	Cerebellar Assessment in Early Multiple Sclerosis. Cerebellum, 2017, 16, 607-611.	2.5	8

#	ARTICLE	IF	CITATIONS
500	Evolving concepts in the treatment of relapsing multiple sclerosis. <i>Lancet</i> , The, 2017, 389, 1347-1356.	13.7	252
501	Headache in the first manifestation of Multiple Sclerosis—Prospective, multicenter study. <i>Brain and Behavior</i> , 2017, 7, e00852.	2.2	13
502	Literature Commentary. <i>Journal of Neuro-Ophthalmology</i> , 2017, 37, 451-457.	0.8	0
503	The Anti-Inflammatory Effects of Oral-Formulated Tacrolimus in Mice with Experimental Autoimmune Encephalomyelitis. <i>Journal of Korean Medical Science</i> , 2017, 32, 1502.	2.5	2
505	Clinically Isolated Syndrome According to McDonald 2010: Intrathecal IgG Synthesis Still Predictive for Conversion to Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2061.	4.1	23
506	<i>Clinical Research in Neurology</i> . , 2017, , 555-571.		0
507	Multiple Sclerosis: Immunopathology and Treatment Update. <i>Brain Sciences</i> , 2017, 7, 78.	2.3	197
508	Thérapeutiques et prise en charge de la sclérose en plaques. , 2017, , 145-216.		1
509	The early diagnosis and treatments in multiple sclerosis. <i>Kosin Medical Journal</i> , 2017, 32, 151.	0.3	0
510	Smoking at time of CIS increases the risk of clinically definite multiple sclerosis. <i>Journal of Neurology</i> , 2018, 265, 1010-1015.	3.6	16
511	Factors associated with early initiation of disease-modifying drug treatment in newly-diagnosed patients with multiple sclerosis. <i>Current Medical Research and Opinion</i> , 2018, 34, 1389-1395.	1.9	0
512	Classification and diagnostic criteria for demyelinating diseases of the central nervous system: Where do we stand today?. <i>Revue Neurologique</i> , 2018, 174, 378-390.	1.5	15
513	Recent developments in interferon-based therapies for multiple sclerosis. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 665-680.	3.1	21
514	<scp>ECTRIMS</scp>/<scp>EAN</scp> guideline on the pharmacological treatment of people with multiple sclerosis. <i>European Journal of Neurology</i> , 2018, 25, 215-237.	3.3	147
515	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 96-120.	3.0	458
516	Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis. <i>Journal of Neurology</i> , 2018, 265, 999-1009.	3.6	21
517	Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. <i>Nature Reviews Neurology</i> , 2018, 14, 75-93.	10.1	115
518	Interferon β -1a and β -1b for patients with multiple sclerosis: updates to current knowledge. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 137-153.	3.0	36

#	ARTICLE	IF	CITATIONS
519	Interferon β for Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a032003.	6.2	116
520	Vitamin D and Multiple Sclerosis: A Comprehensive Review. Neurology and Therapy, 2018, 7, 59-85.	3.2	245
521	Should Spinal MRI Be Routinely Performed in Patients With Clinically Isolated Optic Neuritis?. Journal of Neuro-Ophthalmology, 2018, 38, 502-510.	0.8	1
522	Headache at the Time of First Symptom Manifestation of Multiple Sclerosis: A Prospective, Longitudinal Study. European Neurology, 2018, 80, 115-120.	1.4	13
523	Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis. Arquivos De Neuro-Psiquiatria, 2018, 76, 539-554.	0.8	22
524	Present Drug Therapy of Demyelinating Disorders. Current Drug Therapy, 2018, 13, 25-42.	0.3	0
525	Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course. Journal of Neurology, 2018, 265, 2540-2547.	3.6	38
526	Multiple Sclerosis. Seminars in Neurology, 2018, 38, 212-225.	1.4	113
527	Acute Visual Deficits. , 2018, , 281-302.		0
528	Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731878334.	1.0	21
529	Application of the 2017 Revised McDonald Criteria for Multiple Sclerosis to Patients With a Typical Clinically Isolated Syndrome. JAMA Neurology, 2018, 75, 1392.	9.0	95
530	Should we treat patients with radiologically isolated syndrome (RIS)? Yes. Revue Neurologique, 2018, 174, 689-692.	1.5	2
531	The Way Forward With Vitamin D in Multiple Sclerosis. , 2018, , 175-191.		2
532	Acute and Chronic Therapies in Pediatric Inflammatory Central Nervous System Diseases. Journal of Pediatric Neurology, 2018, 16, 202-216.	0.2	1
533	Steroid inhibition of erythrocyte-derived ATP reduces endothelial cell production of nitric oxide in a 3D-printed fluidic model. Analytical Methods, 2018, 10, 3416-3422.	2.7	4
534	High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome. Multiple Sclerosis Journal, 2019, 25, 958-967.	3.0	31
535	An update on the safety of treating relapsing-remitting multiple sclerosis. Expert Opinion on Drug Safety, 2019, 18, 925-948.	2.4	13
536	Drug Treatment of Clinically Isolated Syndrome. CNS Drugs, 2019, 33, 659-676.	5.9	12

#	ARTICLE	IF	CITATIONS
537	Models and treatments for traumatic optic neuropathy and demyelinating optic neuritis. <i>Developmental Neurobiology</i> , 2019, 79, 819-836.	3.0	21
538	Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101335.	2.0	6
539	The Anti-Inflammatory Effect of Sulforaphane in Mice with Experimental Autoimmune Encephalomyelitis. <i>Journal of Korean Medical Science</i> , 2019, 34, e197.	2.5	21
540	Cost-effectiveness of interferon therapy for multiple sclerosis in Peru: impact of treatment adherence. <i>Journal of Pharmaceutical Health Services Research</i> , 2019, 10, 125-132.	0.6	0
541	Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 131-138.	2.0	15
542	Disease-modifying drugs for multiple sclerosis in Japan: A focus on the 2017 Japanese guidelines and the 2018 supplement. <i>Clinical and Experimental Neuroimmunology</i> , 2019, 10, 49-53.	1.0	1
543	Impact of the McDonald Criteria 2017 on Early Diagnosis of Relapsing-Remitting Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 188.	2.4	52
544	Updates and Controversies in the Management of Acute Optic Neuritis. <i>Asia-Pacific Journal of Ophthalmology</i> , 2019, 7, 251-256.	2.5	6
545	Demyelinating Optic Neuritis and its Subtypes. <i>International Ophthalmology Clinics</i> , 2019, 59, 23-37.	0.7	7
546	MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry. <i>Brain Imaging and Behavior</i> , 2019, 13, 1361-1374.	2.1	27
547	Visual Loss. , 2019, , 101-196.		3
548	Monitoring of Lymphocyte Populations During Treatment with Interferon- β to Predict Multiple Sclerosis Disability Progression. <i>Journal of Interferon and Cytokine Research</i> , 2019, 39, 164-173.	1.2	1
549	Headache in the course of multiple sclerosis: a prospective study. <i>Journal of Neural Transmission</i> , 2019, 126, 131-139.	2.8	11
550	Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. <i>Multiple Sclerosis Journal</i> , 2019, 25, 565-573.	3.0	9
551	Predictors of treatment outcome in patients with paediatric onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 964-975.	3.0	11
552	Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101459.	2.0	56
553	What do we currently know about the clinically isolated syndrome suggestive of multiple sclerosis? An update. <i>Reviews in the Neurosciences</i> , 2020, 31, 335-349.	2.9	4
554	Selective cognitive dysfunction and physical disability improvement after autologous hematopoietic stem cell transplantation in highly active multiple sclerosis. <i>Scientific Reports</i> , 2020, 10, 21286.	3.3	9

#	ARTICLE	IF	CITATIONS
555	The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. <i>Brain</i> , 2020, 143, 2637-2652.	7.6	56
557	Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 437-455.	0.5	63
558	Conversion of clinically isolated syndrome to multiple sclerosis: a prospective study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102262.	2.0	15
559	Stability and Activity of the Hyperglycosylated Human Interferon- β R27T Variant. <i>Scientific Reports</i> , 2020, 10, 8412.	3.3	4
560	Predictive MS risk factors and axonal disintegration. <i>Neurology</i> , 2020, 94, 771-772.	1.1	0
561	Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642091031.	3.5	17
562	Glycosylation Heterogeneity of Hyperglycosylated Recombinant Human Interferon- β (rhIFN- β). <i>ACS Omega</i> , 2020, 5, 6619-6627.	3.5	3
563	<p></p>Interferon-Beta-Induced Headache in Patients with Multiple Sclerosis: Frequency and Characterization</p>. <i>Journal of Pain Research</i> , 2020, Volume 13, 537-545.	2.0	16
564	Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis. <i>Journal of Neuroimmunology</i> , 2020, 347, 577317.	2.3	9
565	Kynurenines in the Pathogenesis of Multiple Sclerosis: Therapeutic Perspectives. <i>Cells</i> , 2020, 9, 1564.	4.1	36
566	Application of the 2017 McDonald criteria for the diagnosis of multiple sclerosis after a first demyelinating event in patients from Argentina. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102043.	2.0	5
567	A novel decision tree approach to predict the probability of conversion to multiple sclerosis in Iranian patients with optic neuritis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102658.	2.0	5
568	Assessment of delayed diagnosis and treatment in multiple sclerosis patients during 1990â€“2016. <i>Acta Neurologica Belgica</i> , 2021, 121, 199-204.	1.1	7
569	Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis. <i>Journal of Neurology</i> , 2021, 268, 1247-1253.	3.6	12
570	Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110396.	3.5	86
571	SÃndrome clÃnico aislado: diagnÃstico y riesgo de desarrollar esclerosis mÃltiple clÃnicamente definida. <i>NeurologÃa</i> , 2021, , .	0.7	1
572	MAGNIMS score predicts long-term clinical disease activity-free status and confirmed disability progression in patients treated with subcutaneous interferon beta-1a. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102790.	2.0	8
573	Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1543-1555.	3.0	33

#	ARTICLE	IF	CITATIONS
574	Kappa-Free Light Chains in CSF Predict Early Multiple Sclerosis Disease Activity. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	26
575	Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS). <i>Neurology International</i> , 2021, 13, 207-223.	2.8	20
576	Nasopharyngeal Type-I Interferon for Immediately Available Prophylaxis Against Emerging Respiratory Viral Infections. <i>Frontiers in Immunology</i> , 2021, 12, 660298.	4.8	8
577	The relationship between multiple sclerosis and periodontal health: a clinical-immunological study. <i>Cukurova Medical Journal</i> , 2021, 46, 436-442.	0.2	0
578	Macular Xanthophylls and Markers of the Anterior Visual Pathway among Persons with Multiple Sclerosis. <i>Journal of Nutrition</i> , 2021, 151, 2680-2688.	2.9	6
579	The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review. <i>CNS Drugs</i> , 2021, 35, 861-880.	5.9	29
581	Evaluation of diagnosis and treatment practices of Brazilian neurologists among patients with multiple sclerosis. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 598-606.	0.8	1
582	Emerging deep learning techniques using magnetic resonance imaging data applied in multiple sclerosis and clinical isolated syndrome patients (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1149.	1.8	5
583	Predicting conversion to multiple sclerosis in patients with radiologically isolated syndrome: a retrospective study. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110306.	3.5	2
585	Visual loss. , 2010, , 103-198.		11
586	Clinically Isolated Syndromes. <i>Blue Books of Neurology</i> , 2010, , 206-218.	0.1	1
587	Imaging of Central Nervous System Demyelinating Disorders. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2016, 22, 1613-1635.	0.8	5
588	Clinically Isolated Syndrome and Early Relapsing Multiple Sclerosis. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 670-688.	0.8	5
589	Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. <i>PLoS ONE</i> , 2012, 7, e38661.	2.5	35
590	Risk Factors for Poor Adherence to Betaferon® Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome. <i>PLoS ONE</i> , 2016, 11, e0157950.	2.5	5
591	Disease Modifying Agents for Multiple Sclerosis. <i>The Open Neurology Journal</i> , 2010, 4, 15-24.	0.4	13
592	Prediction of Conversion from Clinically Isolated Syndrome to Multiple Sclerosis According to Baseline Characteristics: A Prospective Study. <i>Noropsikiyatri Arsivi</i> , 2018, 55, 15-21.	0.3	5
593	Interferon Beta: Analysis of Information on Adverse Reactions and Evaluation of Possibility of Signal Identification. <i>Safety and Risk of Pharmacotherapy</i> , 2019, 7, 84-92.	0.2	1

#	ARTICLE	IF	CITATIONS
594	Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. Health Technology Assessment, 2017, 21, 1-352.	2.8	24
595	Treatment of multiple sclerosis. Annals of Indian Academy of Neurology, 2011, 14, 65.	0.5	10
596	MicroRNAs in blood and cerebrospinal fluid as diagnostic biomarkers of multiple sclerosis and to monitor disease progression. Neural Regeneration Research, 2020, 15, 606.	3.0	61
597	Adherence to First-Line Disease-Modifying Therapy for Multiple Sclerosis in Kuwait. International Journal of MS Care, 2012, 14, 17-24.	1.0	2
598	Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course. International Journal of MS Care, 2012, 14, 105-114.	1.0	19
599	The Combined Effect of Nursing Support and Adverse Event Mitigation on Adherence to Interferon Beta-1b Therapy in Early Multiple Sclerosis. International Journal of MS Care, 2012, 14, 198-208.	1.0	9
600	Longitudinal Follow-up of a Cohort of Patients with Incidental Abnormal Magnetic Resonance Imaging Findings at Presentation and Their Risk of Developing Multiple Sclerosis. International Journal of MS Care, 2014, 16, 111-115.	1.0	7
601	Disease-Related Determinants of Quality of Life 10 Years After Clinically Isolated Syndrome. International Journal of MS Care, 2015, 17, 26-34.	1.0	7
606	Should a young patient with a new diagnosis of optic neuritis have testing and treatment for multiple sclerosis (MS)?, 2009, , 7-12.		0
607	Brain and Cranial Nerve Disorders. , 2010, , 1379-1388.		0
609	Disease Modifying Agents in the Treatment of Multiple Sclerosis. , 2011, , 131-156.		0
610	La terapia della sclerosi multipla. , 2011, , 57-72.		0
612	Emerging oral disease-modifying therapies in multiple sclerosis: a review of the latest clinical evidence. Clinical Investigation, 2011, 1, 1049-1058.	0.0	1
613	Acute Therapies and Disease-Modifying Therapies for Multiple Sclerosis. , 2012, , 273-291.		0
617	Therapy of Multiple Sclerosis. , 2013, , 65-75.		0
618	Neuroimaging in Multiple Sclerosis. , 2013, , 43-64.		0
619	Gesundheitsbezogene Lebensqualit�t (HRQoL). , 2013, , 161-178.		0
620	Neutralisierende Antik�rper. , 2013, , 135-149.		0

#	ARTICLE	IF	CITATIONS
621	Betaferon® â€“ MRI-Daten. , 2013, , 69-77.		0
622	Anja van de Pas (30). , 2013, , 76-77.		0
623	FrÃ¼htherapie bei MS. , 2013, , 39-51.		0
625	VertrÃ¤glichkeit von Interferonen. , 2013, , 151-160.		0
627	Multiple Sclerosis: Impact on Functioning of the Bloodâ€“Brain Barrier. , 2014, , 143-160.		0
629	Shedding Light on Vitamin D and Multiple Sclerosis. , 2016, , 327-345.		0
630	Switching or Discontinuing Disease-Modifying Therapies for Multiple Sclerosis. CONTINUUM Lifelong Learning in Neurology, 2016, 22, 851-863.	0.8	7
631	Differential Diagnosis between Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. Journal of the Korean Neurological Association, 2016, 34, 290-296.	0.1	4
632	Escalation therapy in multiple sclerosis. Neurologie Pro Praxi, 2016, 17, 407-411.	0.1	0
633	Diagnostic positif de la sclÃ©rose en plaques. , 2017, , 79-111.		0
634	Acute Disturbance/Loss of Vision. Ocular Trauma, 2018, , 57-94.	0.1	0
635	Role of retrobulbar dexamethasone in the treatment of optic neuritis. Egyptian Retina Journal, 2018, 5, 32.	0.2	0
636	Depression in multiple sclerosis. Neurologie Pro Praxi, 2018, 19, 114-122.	0.1	0
637	Drugs for Soft Tissue Autoimmune Disorders. , 2019, , 751-775.		0
639	Histoire naturelle de la sclÃ©rose en plaques. , 2019, , 107-135.		0
640	Interferon Beta-1b for the Treatment of Multiple Sclerosis â€“ More than 10 Years of Experience. Acta Marisiensis - Seria Medica, 2019, 65, 12-18.	0.3	0
641	Emerging Trends in Optic Neuritis and Associated Demyelinating Diseases. Current Practices in Ophthalmology, 2020, , 1-15.	0.1	0
642	Impact of delayed treatment on exacerbations of multiple sclerosis among Puerto Rican patients. , 2019, 10, 200.		2

#	ARTICLE	IF	CITATIONS
643	Disease-Modifying Agents. Current Clinical Neurology, 2020, , 137-157.	0.2	0
644	Drug Safety Issues in Therapy COVID-19. Russian Archives of Internal Medicine, 2020, 10, 165-187.	0.2	2
645	Multiple Sclerosis Diagnostic Criteria. Neurology, 2022, 98, 12-13.	1.1	2
646	Cerebrospinal Fluid IgM and Oligoclonal IgG Bands in Multiple Sclerosis: A Meta-Analysis of Prevalence and Prognosis. Brain Sciences, 2021, 11, 1444.	2.3	5
647	Interferon-beta injection in multiple sclerosis patients is related to the induction of headache and flu-like pain symptoms: a systematic review and meta-analysis of randomised controlled trials. Current Neuropharmacology, 2021, 19, .	2.9	1
648	The Increasing Role of Kappa Free Light Chains in the Diagnosis of Multiple Sclerosis. Cells, 2021, 10, 3056.	4.1	17
649	EMDR treatment for anxiety in MS patients: A pilot study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732097438.	1.0	6
650	Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. Biologics: Targets and Therapy, 2009, 3, 369-76.	3.2	28
651	Early stage and long term treatment of multiple sclerosis with interferon-beta. Biologics: Targets and Therapy, 2009, 3, 257-71.	3.2	8
653	Body mass index as a predictor of MS activity and progression among participants in BENEFIT. Multiple Sclerosis Journal, 2022, 28, 1277-1285.	3.0	12
654	The need for a strategic therapeutic approach: multiple sclerosis in check. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232110630.	2.5	14
655	Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosisâ€”from diagnosis to prediction of disease activity. Wiener Medizinische Wochenschrift, 2022, 172, 337-345.	1.1	9
656	Pathways to cures for multiple sclerosis: A research roadmap. Multiple Sclerosis Journal, 2022, 28, 331-345.	3.0	9
658	Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment. CNS Drugs, 2022, 36, 45-59.	5.9	21
660	Meta-Analysis of Two Human RNA-seq Datasets to Determine Periodontitis Diagnostic Biomarkers and Drug Target Candidates. International Journal of Molecular Sciences, 2022, 23, 5580.	4.1	6
661	The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome. Multiple Sclerosis and Related Disorders, 2022, 68, 104143.	2.0	7
662	Long-term treatment for multiple sclerosis with interferon beta-1b. Outcomes of an open, retrospective, observational study. Zhurnal Nevrologii I Psikhiiatrii Imeni S S Korsakova, 2022, 122, 96.	0.7	1
663	The Brave New World of Early Treatment of Multiple Sclerosis: Using the Molecular Biomarkers CXCL13 and Neurofilament Light to Optimize Immunotherapy. Biomedicines, 2022, 10, 2099.	3.2	5

#	ARTICLE	IF	CITATIONS
664	Quality of life in people with multiple sclerosis receiving glatiramer acetate or interferon in Greek clinical practice. <i>Neurodegenerative Disease Management</i> , 0, , .	2.2	0
665	Controversias en neuroinmunología: esclerosis múltiple, vacunación, SARS-CoV-2 y otros dilemas. <i>Biomedica</i> , 2022, 42, 78-99.	0.7	0
666	Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome. <i>Annals of Neurology</i> , 2023, 93, 604-614.	5.3	27
667	Blood Metabolomics May Discriminate a Sub-Group of Patients with First Demyelinating Episode in the Context of RRMS with Increased Disability and MRI Characteristics Indicative of Poor Prognosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14578.	4.1	0
668	Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a. <i>Journal of Neurology</i> , 2023, 270, 2271-2282.	3.6	1
669	Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies. <i>Frontiers in Neurology</i> , 0, 14, .	2.4	1
670	Presentación clínica de primer evento desmielinizante en pediatría. <i>Revista De La Facultad De Ciencias Medicas De Cordoba</i> , 2023, 80, 52-54.	0.3	0
671	Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study. <i>EBioMedicine</i> , 2023, 91, 104573.	6.1	0
672	Early Treatment for Multiple Sclerosis. <i>Neurology</i> , 2023, 101, 549-550.	1.1	0
673	MRI assessment of cervical spinal cord cross-sectional area in patients with multiple sclerosis. <i>Journal of Neurosciences in Rural Practice</i> , 0, .	0.8	0
674	Real-life evaluation of the 2017 McDonald criteria for relapsing–remitting multiple sclerosis after a clinically isolated syndrome confirms a gain in time-to-diagnosis. <i>Journal of Neurology</i> , 0, , .	3.6	0
675	Disease-modifying therapies in multiple sclerosis: A focused review of rituximab. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2023, 133, 550-564.	2.5	1
676	Clinically isolated syndrome: Diagnosis and risk of developing clinically definite multiple sclerosis. <i>Neurología (English Edition)</i> , 2023, , .	0.4	1
677	Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis. <i>The Cochrane Library</i> , 2023, 2023, .	2.8	0
678	Bioavailable central nervous system disease-modifying therapies for multiple sclerosis. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
679	MULTIPLE SCLEROSIS: AN EMERGENCY MEDICINE-FOCUSED NARRATIVE REVIEW. <i>Journal of Emergency Medicine</i> , 2023, , .	0.7	0
680	Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines. <i>Multiple Sclerosis and Related Disorders</i> , 2024, 83, 105435.	2.0	0
681	Disease-modifying therapies. , 2024, , 135-206.		0

#	ARTICLE	IF	CITATIONS
682	Novel biomarkers and interferon signature in secondary progressive multiple sclerosis. Journal of Neuroimmunology, 2024, 389, 578328.	2.3	0
684	Radiologically isolated syndromes: to treat or not to treat?. Journal of Neurology, 2024, 271, 2370-2378.	3.6	0